Tilorone is the first recognized synthetic, small molecular weight compound that is an orally active interferon inducer. It is used as an antiviral drug in some countries which do not require double-blind placebo-controlled studies, including Russia. It is a lipophilic, amphiphilic fluorenone derivative administered as a salt formulation for oral dosing and characterized by intracellular accumulation and affinity for endosomal compartments. Pharmacologically it acts as an immune response modifier with reported induction of type I interferons and downstream antiviral gene expression in preclinical models. Tilorone is formulated for solid oral dosage forms, typically as a dihydrochloride or other salt to improve handling and aqueous properties, and its physical-chemical profile requires control of residual solvents, counterion content, and polymorphic form during manufacture to ensure consistent bioavailability.
Parent: Tilorone
Typical analytical control of Tilorone includes assay and related-substance limits consistent with small-molecule active pharmaceutical ingredient quality standards. Common related compounds and impurities observed during synthesis and storage include O-dealkylation and N-dealkylation products, monoalkylated analogs, oxidative degradation products on the fluorenone core, and process-related residuals from alkylation reagents. Typical specification ranges used in quality control programs are assay not less than 98.0 percent, individual unspecified impurities generally limited to 0.5 to 1.0 percent, and total impurities limited to 2.0 percent or less, with reporting thresholds and identification performed by HPLC and LC-MS. Additional controls include limits for heavy metals, typically in the low ppm range, and classification and limits for residual solvents per ICH Q3C; exact impurity profiles and quantitative limits should be derived from the specific synthetic route, salt form, and regulatory requirements applicable to the product.
Tilorone acts primarily as an inducer of type I interferon responses. It is taken up by cells and accumulates in endosomal and intracellular compartments where it triggers signaling cascades that lead to increased transcription and release of interferon alpha and beta and activation of interferon-stimulated genes. The downstream effect is a broad-spectrum antiviral state in treated cells rather than a direct virus-targeting mechanism. Mechanistic details are based on preclinical and in vitro studies and remain an area of active study.
Efficacy data for Tilorone are mixed and depend on the model system and clinical context. Preclinical studies and some open-label or non-double-blind clinical reports indicate antiviral and immunomodulatory activity against a range of viruses. However, high-quality randomized, double-blind, placebo-controlled clinical trial data meeting international regulatory standards are limited or absent in jurisdictions where it is marketed. Effectiveness and approved indications therefore vary by country and local regulatory assessment.
Amixin is a trade name under which tilorone formulations are marketed in some countries. The tablet form is used as an antiviral and immunomodulatory agent for treatment or prophylaxis of certain viral respiratory infections and other indications as authorized locally. Dosage regimens, approved indications, and labeling differ by market; users should follow local prescribing information and regulatory guidance for appropriate use.
Solubility depends on the chemical form. The free base of tilorone is sparingly soluble in water and shows greater solubility in organic solvents such as methanol, ethanol, and DMSO. Salt forms, for example the dihydrochloride, are substantially more water soluble and are typically used for oral tablet formulation to achieve acceptable dissolution and bioavailability. Exact solubility values vary with temperature, pH, counterion, and formulation excipients, and should be measured for the specific batch and salt form in use.
